How The Parts Add Up: VONE Targets $274
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 22 2024
0mins
Should l Buy APLS?
Source: NASDAQ.COM
Vanguard Russell 1000 ETF Analysis: The Vanguard Russell 1000 ETF (VONE) has an implied analyst target price of $274.39, indicating a potential upside of 10.34% from its current trading price of $248.67.
Notable Holdings with Upside Potential: Key holdings within VONE, such as Apellis Pharmaceuticals (APLS), Peloton Interactive (PTON), and Intra-Cellular Therapies (ITCI), show significant upside potential based on analysts' target prices, suggesting optimism about their future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy APLS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on APLS
Wall Street analysts forecast APLS stock price to fall
14 Analyst Rating
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 41.120
Low
19.00
Averages
31.69
High
48.00
Current: 41.120
Low
19.00
Averages
31.69
High
48.00
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Rights Protection: Monteverde Law Firm is investigating Citizens National Corporation (CZNL) related to its sale to Peoples Bancorp, Inc., where shareholders are expected to receive 2.10 common shares of Peoples and $8.00 in cash per share, aiming to ensure fair compensation for shareholders in the transaction.
- Merger Transaction Analysis: Helix Energy Solutions Group, Inc. (HLX) is merging with Hornbeck Offshore Services, Inc., which will allow Helix shareholders to own approximately 45% of the combined company, indicating strong competitive positioning post-merger.
- Pharmaceutical Acquisition Dynamics: Apellis Pharmaceuticals, Inc. (APLS) is set to be acquired by Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and two contingent payments of $2.00 each, reflecting confidence in meeting future sales targets.
- Biotech Transaction Progress: Soleno Therapeutics, Inc. (SLNO) is being acquired by Neurocrine Biosciences, Inc., with shareholders expected to receive $53.00 per share in cash, and a shareholder vote scheduled for May 15, 2026, showcasing the company's proactive strategy in the biotech sector.
See More
Biogen Reports Earnings Beat, Shares Surge 6%
- Earnings Beat: Biogen reported total revenue of $2.48 billion for Q1 2026, reflecting a 2% year-over-year increase that surpassed the consensus estimate of $2.25 billion, demonstrating resilience in a competitive biotech landscape.
- Profitability Improvement: The company's attributable net income rose by 19% to $529 million, or $3.57 per share, significantly exceeding analysts' expectations of $2.95 per share, indicating a notable enhancement in profitability.
- Sales Growth: Sales of Leqembi surged by 74% to $168 million, serving as a key driver for revenue growth, while Skyclarys also exhibited strong double-digit growth, showcasing Biogen's success in new drug development.
- Guidance Cut: Despite the strong earnings report, Biogen lowered its full-year adjusted net income guidance to $14.25 to $15.25 per share, down $1 from the previous forecast of $15.25 to $16.25, reflecting the impact of R&D expenses, although the ongoing acquisition of Apellis Pharmaceuticals is expected to further strengthen the company's market position.
See More
Market Preview: Tech Giants Earnings Day
- Fed Rate Decision: The Federal Reserve is expected to keep interest rates unchanged this afternoon, with market participants closely watching Chair Powell's press conference, which could influence investor confidence in the economy's future.
- Tech Giants Earnings: Alphabet, Amazon, Meta, and Microsoft are set to report earnings after the bell, with high expectations for Alphabet's cloud and advertising growth, while Amazon must discuss more than just its cloud success to maintain its stock price.
- Seagate Strong Performance: Seagate reported a strong quarter that exceeded expectations, driven by surging demand for data storage technology in the AI era, with its stock up 600% over the past year and an additional 16% increase today.
- Visa Quarterly Results: Visa's quarterly performance was robust, with limited disruption from the Middle East, announcing a $20 billion buyback plan and projecting low double-digit to low-teens revenue growth for the year, resulting in a stock price increase of over 5%.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Clear Channel Outdoor Holdings, Inc. (NYSE:CCO) for potential fiduciary duty breaches related to its sale to Mubadala Capital and TWG Global at $2.43 per share, which may disadvantage shareholders.
- Shareholder Rights: Enhabit, Inc. (NYSE:EHAB) is being sold to Kinderhook Industries, LLC for $13.80 per share in cash, prompting Halper Sadeh LLC to encourage shareholders to inquire about their rights and options, potentially impacting the transparency and fairness of the transaction.
- Potential Gains: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is selling to Biogen Inc. for $41.00 per share in cash plus two non-transferable contingent value rights of $2.00 each, contingent on meeting specific sales thresholds, which may limit superior competing offers.
- Legal Support: Halper Sadeh LLC represents investors globally, seeking increased consideration and additional disclosures to ensure that the legal rights of affected shareholders are upheld and that they receive appropriate remedies for any corporate misconduct.
See More
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, which may involve violations of shareholder rights.
- Shareholder Rights Protection: The transaction between Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) and Biogen Inc. includes $41.00 per share in cash and two non-transferable rights of $2.00 each, with Halper Sadeh LLC potentially seeking increased compensation and additional disclosures for shareholders.
- Merger Impact: Helix Energy Solutions Group, Inc. (NYSE: HLX) is merging with Hornbeck Offshore Services, Inc., resulting in Helix shareholders owning approximately 45% of the combined entity, prompting Halper Sadeh LLC to assess the implications for shareholders.
- Legal Fee Arrangement: Halper Sadeh LLC offers legal services on a contingency fee basis, allowing shareholders to consult on their rights and options without upfront costs, ensuring their legal interests are protected.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Rights Protection: Monteverde Law Firm is investigating Citizens National Corporation (CZNL) related to its sale to Peoples Bancorp, Inc., where shareholders are expected to receive 2.10 common shares of Peoples and $8.00 in cash per share, aiming to ensure fair compensation for shareholders in the transaction.
- Merger Transaction Analysis: Helix Energy Solutions Group, Inc. (HLX) is merging with Hornbeck Offshore Services, Inc., which will allow Helix shareholders to own approximately 45% of the combined company, indicating strong competitive positioning post-merger.
- Pharmaceutical Acquisition Dynamics: Apellis Pharmaceuticals, Inc. (APLS) is set to be acquired by Biogen, Inc., with shareholders expected to receive $41.00 per share in cash and two contingent payments of $2.00 each, reflecting confidence in meeting future sales targets.
- Biotech Transaction Progress: Soleno Therapeutics, Inc. (SLNO) is being acquired by Neurocrine Biosciences, Inc., with shareholders expected to receive $53.00 per share in cash, and a shareholder vote scheduled for May 15, 2026, showcasing the company's proactive strategy in the biotech sector.
See More
Biogen Reports Earnings Beat, Shares Surge 6%
- Earnings Beat: Biogen reported total revenue of $2.48 billion for Q1 2026, reflecting a 2% year-over-year increase that surpassed the consensus estimate of $2.25 billion, demonstrating resilience in a competitive biotech landscape.
- Profitability Improvement: The company's attributable net income rose by 19% to $529 million, or $3.57 per share, significantly exceeding analysts' expectations of $2.95 per share, indicating a notable enhancement in profitability.
- Sales Growth: Sales of Leqembi surged by 74% to $168 million, serving as a key driver for revenue growth, while Skyclarys also exhibited strong double-digit growth, showcasing Biogen's success in new drug development.
- Guidance Cut: Despite the strong earnings report, Biogen lowered its full-year adjusted net income guidance to $14.25 to $15.25 per share, down $1 from the previous forecast of $15.25 to $16.25, reflecting the impact of R&D expenses, although the ongoing acquisition of Apellis Pharmaceuticals is expected to further strengthen the company's market position.
See More
Market Preview: Tech Giants Earnings Day
- Fed Rate Decision: The Federal Reserve is expected to keep interest rates unchanged this afternoon, with market participants closely watching Chair Powell's press conference, which could influence investor confidence in the economy's future.
- Tech Giants Earnings: Alphabet, Amazon, Meta, and Microsoft are set to report earnings after the bell, with high expectations for Alphabet's cloud and advertising growth, while Amazon must discuss more than just its cloud success to maintain its stock price.
- Seagate Strong Performance: Seagate reported a strong quarter that exceeded expectations, driven by surging demand for data storage technology in the AI era, with its stock up 600% over the past year and an additional 16% increase today.
- Visa Quarterly Results: Visa's quarterly performance was robust, with limited disruption from the Middle East, announcing a $20 billion buyback plan and projecting low double-digit to low-teens revenue growth for the year, resulting in a stock price increase of over 5%.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Clear Channel Outdoor Holdings, Inc. (NYSE:CCO) for potential fiduciary duty breaches related to its sale to Mubadala Capital and TWG Global at $2.43 per share, which may disadvantage shareholders.
- Shareholder Rights: Enhabit, Inc. (NYSE:EHAB) is being sold to Kinderhook Industries, LLC for $13.80 per share in cash, prompting Halper Sadeh LLC to encourage shareholders to inquire about their rights and options, potentially impacting the transparency and fairness of the transaction.
- Potential Gains: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is selling to Biogen Inc. for $41.00 per share in cash plus two non-transferable contingent value rights of $2.00 each, contingent on meeting specific sales thresholds, which may limit superior competing offers.
- Legal Support: Halper Sadeh LLC represents investors globally, seeking increased consideration and additional disclosures to ensure that the legal rights of affected shareholders are upheld and that they receive appropriate remedies for any corporate misconduct.
See More
